Related Experiment Video
Updated: Nov 20, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Results with Posterior Scleral Reinforcement for Progressive Highly Myopic Children in Hungary
Noémi Széll1, Adrienn Boross1, Andrea Facskó2
1Ophthalmologie, Kenézy Gyula University Hospital of Debrecen Medical University, Debrecen, Hungary.
Insights
Posterior scleral reinforcement significantly slowed myopia progression in children. This surgical method effectively reduced axial length and refractive error increases, preventing long-term vision loss.
Area of Science:
- Ophthalmology
- Pediatric Ophthalmology
- Surgical Interventions
Background:
- Progressive high myopia poses a risk for serious ocular complications.
- Early intervention is crucial to mitigate long-term visual impairment.
Purpose of the Study:
- To evaluate the efficacy of posterior scleral reinforcement using the Snyder-Thompson method in managing progressive high myopia in children.
- To compare outcomes between surgically treated eyes and a control group.
Main Methods:
- Retrospective analysis of 38 eyes from 32 patients undergoing Snyder-Thompson posterior scleral reinforcement.
- Comparison with a control group of 14 eyes from 9 age- and myopia-matched children.
- Assessment of best-corrected visual acuity, refractive error (spherical equivalent), and axial length pre- and post-operatively.
Main Results:
- Significantly lower myopic progression in the operated group (axial length: 0.21 mm/year vs. 0.49 mm/year; refractive error: 0.18 D vs. 0.6 D).
- Greater visual improvement observed in eyes that underwent surgery compared to the control group.
- No significant factors identified as influencing myopia progression; no serious complications reported.
Conclusions:
- Posterior scleral reinforcement (Snyder-Thompson method) is a safe and effective surgical option for retarding pathological myopia progression.
- The procedure helps prevent degenerative lesions and irreversible vision loss in the long term.
- This technique offers a valuable approach to managing high myopia in pediatric patients.
Purpose:
We have been performing posterior scleral reinforcement in our ophthalmological department since 1992 on progressive highly myopic eyes. Here, we report on our results with this technique in the foregoing 7 years in a retrospective comparative design.
Methods:
Thirty-eight eyes of 32 patients, operated according to Snyder-Thompson's method, were enrolled in this study, and a control group of 9 age- and myopia-matched children's 14 eyes was built for comparison. Pre- and postoperative best-corrected visual acuity, subjective refractive error (spherical equivalent of spectacle dioptres), and axial length were recorded. Changes within groups were calculated, as well as baseline parameters and their changes during follow-up, and compared between the groups. Correlation analysis was performed to identify factors that could influence myopia progression.
Results:
Myopic progression was significantly lower in the operated than in the nonoperated group, both in terms of mean annual axial length as well as refractive error changes (0.21 ± 0.08 mm versus 0.49 ± 0.19 mm and 0.18 ± 0.29 D versus 0.6 ± 0.33 D, respectively). Mean overall visual improvement was more explicit in operated eyes as compared to those left untreated (0.15 ± 0.09 versus 0.01 ± 0.1). No association of any factor with myopia progression could be identified. We encountered no serious or lasting complications.
Conclusion:
In our clinical practice, posterior scleral reinforcement according to Snyder-Thompson proved to be a safely applicable and effective surgical method to stop or significantly retard pathological increases in axial length and dioptres, and thus can help prevent the onset of myopic degenerative lesions, and irreversible visual impairment in the long run.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment